Company Insights

MLSS customer relationships

Explore interactive graphBrowse insights index

MLSS customers relationship map

Milestone Scientific (MLSS) — Customer Relationships, Revenue Sources, and What They Signal for Investors

Milestone Scientific develops computer-controlled anesthetic delivery devices for dental and medical markets and monetizes through device sales, accessories, and consumables sold both directly and through distributors, supplemented by an expanding e‑commerce channel and targeted institutional contracting. Revenue is concentrated, margins are negative, and the company is leveraging direct online sales and government procurement channels to scale adoption of its CompuFlo® and STA product lines. For investors assessing customer risk and growth runway, the mix of small institutional accounts, distributor relationships, rapid e‑commerce adoption, and a newly awarded Federal Supply Schedule are the most consequential dynamics. Learn more at https://nullexposure.com/.

Quick read: the operating model in one line

Milestone sells precision anesthetic delivery systems to dental offices and medical clinics through a hybrid route-to-market—direct e‑commerce, exclusive/non‑exclusive distributors, and increasingly, government procurement—while consumables and service convert installed devices into recurring revenue.

Two named customer relationships, and why they matter

Milestone’s publicly disclosed customer relationships are limited but illustrative: a small clinic purchase tied to a board member and an initial institutional deployment of CompuFlo® into a pain management clinic. These entries signal early commercial traction in medical pain management and modest single-account spend levels consistent with a small-cap medical devices firm.

Customer-by-customer breakdown (every disclosed relationship)

  • STEMMEE — University Pain Medicine Center
    Milestone sold medical products to STEMMEE, where Dr. D. Demesmin, a company board member, serves as CEO, with purchases totaling $21,000 for the year ended December 31, 2024, transacted under the same terms Milestone applies to other U.S. pain clinics. This is a small, contract-level sale reflecting early clinical adoption rather than a large institutional deployment, and it is disclosed in Milestone’s 2024 Form 10‑K. (Source: Milestone Scientific 2024 Form 10‑K.)

  • The Painless Center — Tenafly, New Jersey
    Milestone commenced sales of the CompuFlo® Epidural System to The Painless Center in Tenafly, NJ, marking a concrete medical-clinic customer for its epidural product commercialization efforts. That sale was reported publicly in a company press release covered by MarketScreener on July 17, 2025. (Source: MarketScreener news report, July 17, 2025.)

What the customer list tells investors about concentration and scale

  • Spend scale is low and dispersed. The explicit purchase figures—$21,000 from STEMMEE and the limited disclosure on The Painless Center—fit the profile of a company at early commercial scale, where single‑account revenues are modest and rely on a growing installed base to generate consumables revenue.
  • No single large anchor customer disclosed. There is no evidence of a major revenue concentration with a single purchaser; financials show total revenue of roughly $8.97 million on a trailing‑twelve‑month basis, underscoring that growth must come from many small accounts or distributor expansion.
  • Board ties to customers exist. The STEMMEE relationship is explicitly linked to a board member, which is commercially useful but raises governance and related‑party scrutiny for investors; the transaction was disclosed in the 2024 10‑K.

Company-level constraints that shape the commercial outlook

Treat the following as firm‑level operating signals that affect contracting posture, maturity, and go‑to‑market risk:

  • Government procurement access: On November 26, 2024, Milestone announced approval onto the Federal Supply Schedule (FSS/GSA Schedule) for the CompuFlo® Epidural System. This places Milestone in a preferred procurement channel for federal agencies and institutional buyers, which improves long‑term sales visibility but imposes government contracting compliance and payment-cycle disciplines. (Source: company disclosure, Nov 26, 2024.)

  • Global distribution footprint: The company reports that dental devices are sold in the U.S., Canada, and in more than 41 other countries. Geographic reach reduces single‑market concentration but increases complexity around distributor management and regulatory footprint. (Source: company disclosure.)

  • Hybrid route-to-market: Milestone sells STA systems directly via an online portal in the U.S. and uses both exclusive and non‑exclusive distributors globally. The mix delivers flexibility—direct margin capture from e‑commerce and scale through distributors—but creates multi-channel channel conflict and variable revenue recognition dynamics. (Source: company disclosure.)

  • E‑commerce maturity and impact: Milestone launched an e‑commerce platform on January 3, 2023; e‑commerce accounted for 60% of net product sales in 2024, up from 48% in 2023, showing rapid channel shift and meaningful direct-to-practice traction. This is a material commercial acceleration and a driver of gross margin capture. (Source: company disclosure for FY2023–FY2024.)

  • Historical distributor spend signal: The company disclosed approximately $270,000 of sales to Milestone China or its agents in 2023 and no sales to that channel in 2024. This indicates modest historical revenue tied to a specific international agent and a rapid retraction or reorganization of that channel by 2024—an indicator of distribution volatility in select markets. (Source: company filings for years ended Dec 31, 2023 and Dec 31, 2024.)

Investment implications: risk and opportunity map

  • Opportunity: Rapid e‑commerce penetration is the clearest lever for margin improvement and customer density, since 60% of product sales already flow through the direct channel. If the company converts device buyers into recurring consumable purchasers, lifetime value could improve materially.
  • Risk: Revenue scale is small and margins are negative (Operating Margin TTM -52.5%, Profit Margin -63.8%). Growth must outpace existing operating losses to reach break‑even. The customer base shown in disclosures is nascent and dispersed, leaving sales execution and distributor relationships as critical operational risks.
  • Contracting posture: Government procurement placement via the FSS is strategically positive—it opens state and federal institutional buyers and can create a steady demand stream—but it requires disciplined compliance and may lengthen receivable cycles.
  • Governance and concentration: Board-level relationships to buying entities (the STEMMEE example) require transparency; investors should monitor related‑party disclosures and how such ties affect commercial terms and scale.

Bottom line and next steps for due diligence

Milestone Scientific shows early commercial traction in medical pain management and a strong pivot to direct e‑commerce sales, but overall revenue remains small and profitability is negative. Investors should prioritize monitoring: (1) continued expansion of CompuFlo® institutional deployments via the GSA channel, (2) growth and retention metrics from the e‑commerce channel, and (3) distributor stability in international markets.

For a deeper look at Milestone’s customer relationships, contracting posture, and how these operational signals map to exposure and growth scenarios, visit https://nullexposure.com/.

Join our Discord